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Abstract 
Background: Angiogenesis is a hallmark feature in the initiation, progression and growth of tumour. There are vari-
ous factors for promotion of angiogenesis on one hand and on the other hand, biomolecules have been reported to 
inhibit cancer through anti-angiogenesis mechanism. Biomolecules, for instance, luteolin, lectin and lupeol are known 
to suppress cancer. This study aims to compare and evaluate the biomolecule(s) like luteolin, lupeol and lectin on 
CAM assay and HT-29 cell culture to understand the efficacy of these drugs.
Method: The biomolecules have been administered on CAM assay, HT-29 cell culture, cell migration assay. Further-
more, bioinformatics analysis of the identified targets of these biomolecules have been performed.
Result: Luteolin has been found to be better in inhibiting angiogenesis on CAM assay in comparison to lupeol and 
lectin. In line with this study when biomolecules was administered on cell migration assay via scratch assay method. 
We provided evidence that Luteolin was again found to be better in inhibiting HT-29 cell migration. In order to iden-
tify the target sites of luteolin for inhibition, we used software analysis for identifying the best molecular targets of 
luteolin. Using software analysis best target protein molecule of these biomolecules have been identified. VEGF was 
found to be one of the target of luteolin. Studies have found several critical point mutation in VEGF A, B and C. Hence 
docking analysis of all biomolecules with VEGFR have been performed. Multiple allignment result have shown that 
the receptors are conserved at the docking site.
Conclusion: Therefore, it can be concluded that luteolin is not only comparatively better in inhibiting blood vessel in 
CAM assay, HT-29 cell proliferation and cell migration assay rather the domain of VEGFR is conserved to be targeted by 
luteolin, lupeol and lectin.
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Background
Angiogenesis process is regulated by several factors that 
have a critical role in governing the initiation and pro-
gression of tumour. Angiogenic factors such as bFGF, 
HGF, VEGF, hyluronatelyase, collagenase, MMP sup-
ports the formation of new blood vessels. In addition, cell 
cycle markers, for instance, cyclin A2, Cyclin Dependent 
Kinase-2, 6 and MAPK1, 14, 10 promote the tumour pro-
gression whereas caspase 3 inhibits the tumour progres-
sion. Mounting evidence is suggesting the critical role of 
cyclin inhibitors, and inducers of apoptotic markers in 
cancer therapy. Furthermore, several biomolecules elicit 
the anti-cancerous property such as, luteolin, lectin and 
lupeol but comparative studies in terms of anti-angio-
genic activity remain unsettled.
Luteolin is a flavonoid; lupeol is a triterpene and lec-
tin is a protein possessing carbohydrate. Flavonoids 
are polyphenols that play an important role in defend-
ing plant cells against microorganisms, insects, and UV 
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irradiation, luteolin sensitizes cancer cells to therapeu-
tic-induced cytotoxicity through signaling pathways like 
PI3K/Akt [1], NF-kB [2], X-linked inhibitor of apoptosis 
protein and stimulating apoptosis pathways that induce 
p53. Luteolin has a C6–C3–C6 structure and possesses 
two benzene rings, a third, oxygen-containing (C) ring, 
and a 2–3 carbon double bond. Luteolin also possesses 
hydroxyl groups at carbons 5, 7, 3′, and 4′ positions. The 
hydroxyl moieties and 2–3 double bond are important 
structure features in luteolin that are associated with its 
biochemical and biological activities. Numerous stud-
ies have highlighted that luteolin is often glycosylated in 
plants, and the glycoside is hydrolyzed to free luteolin 
during absorption. Moreover, some portion of luteolin 
is converted to glucuronides when passing through the 
intestinal mucosa. Luteolin is heat stable and losses due 
to cooking are relatively low and may suppress VEGF [3, 
4] expression by inhibiting transcription factor HIF-1α 
through p53-mediated proteasomal degradation.
Additionally, luteolin can suppress VEGF-induced 
signaling in endothelial cells. Luteolin effectively blocked 
activation of the VEGF receptor and its downstream 
molecule PI3K/Akt and PI3K/p70S6 kinase pathways, 
which may directly contribute to luteolin-induced anti-
angiogenesis, resulting in suppression of proliferation 
and survival of human umbilical vein endothelial cells. 
Luteolin may also suppress angiogenesis by stabilizing 
hyaluronic acid, a neovascularization barrier. Hyalu-
ronic acid is one of the most abundant constituents of 
the extracellular matrix that blocks neo vacuole forma-
tion and extension. An enzyme hyaluronidase catalyzes 
hyaluronic acid to break the barrier and to promote 
angiogenesis through the processed product. Further, 
oligosaccharides generated from hyaluronic acid bind 
to the CD44 receptor on the membranes of endothelial 
cells to trigger their proliferation, migration, and eventu-
ally angiogenesis. Luteolin is a strong inhibitor of hya-
luronidase and maintains the neovascularization barrier. 
Moreover, tumor angiogenesis is dependent on the activ-
ity of MMPs where luteolin is a potent MMP inhibitor 
that attenuates MMP expression [5] through suppressing 
NF-κB or directly inhibiting MMP activity. These facts 
reflect that indeed luteolin is an important biomolecule 
for cancer therapy.
Another biomolecule, lupeol is a dietary triterpene 
that is important structural components of plant mem-
branes, and free triterpenes serve to stabilize phospho-
lipid bilayers in plant cell membranes just as cholesterol 
does in animal cell membranes. Most triterpenes contain 
28 or 29 carbons and one or two carbon–carbon double 
bonds, typically one in the sterol nucleus and sometimes 
a second in the alkyl side chain. Triterpenes are natural 
components of human diets. The chemical formula of 
lupeol is C30H50O and its melting point is 215–216  °C. 
Properties computed from the structure of Lupeol show 
that it has a molecular weight of 426.7174 (g/mol), 
H-Bond donor 1, H-Bond acceptor1, rotatable bond 
count 1, exact mass 426.386166. Studies have shown that 
topical application of Lupeol (40  mg/kg/three times a 
week) for 28 weeks can significantly decrease the tumor 
burden, its multiplicity and increase the latency period 
in the mouse model. The anti-tumor promotion effects 
of lupeol were observed to be associated with its poten-
tial to modulate signaling pathways such as nuclear factor 
kappa B (NFκB) and the phosphatidylinositol 3-kinase 
(PI3K)/Akt (protein kinase B pathway) [6], which are 
reported to play an important role during tumorigen-
esis. Lupeol inhibits growth of highly metastatic tumors 
of human melanoma origin by modulating the ratio of 
Bcl-2 and Bax protein [7] levels in vitro and in vivo. Fur-
ther, lupeol significantly inhibits the growth of metastatic 
melanoma cells harboring constitutive activation of Wnt/
β-catenin [8, 9] signaling. Other reports have shown that 
lupeol administered orally in a dose of 2  g/kg has been 
reported to produce no adverse effects in rats and mice, 
and after 96 h of observation, no mortality was recorded. 
Moreover, Lupeol has also been reported to affect angio-
genic gene like MMP and VEGF [10]. Taken together, 
these studies provide convincing evidence that lupeol is a 
non-toxic but highly potent chemo preventive and chem-
otherapeutic agent for cancer therapy.
Lectins are a group of glycoprotein playing a critical 
role in diagnosis of cancer [11–13] whereas targeting of 
lectins can increase the efficacy of anti-VEGF treatment 
[14]. On contrary, there are reports claiming that lec-
tins promote angiogenesis [15]. Lectin in combination 
with RNAse called as Leczyme [16] has also been used 
for cancer therapy. Another feature of lectin that induces 
apoptosis and kills cancerous cells [17, 18] and thus lectin 
can qualify a good candidate for anti-cancer effect. It will 
be interesting to investigate which will be better in inhib-
iting angiogenesis.
In order to understand the anti-angiogenic efficacy of 
these drugs, chick chorio-allantoic-membrane (CAM) 
assay has been performed, which is one of the most 
acceptable and well characterized angiogenesis assays. 
Retinoic acid, a known inhibitor of VEGF and an angio-
genesis marker that have been taken as positive control.
In this study, we investigate about the comparative 
anti-angiogenic effects of biomolecules i.e. luteolin, lec-
tin and lupeol on CAM assay, HT-29 cell line and HT-29 
cell migration assay. We also aim to investigate about the 
docking of these biomolecules with its molecular target 
site for inhibiting cancer.
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Method
Structure of Biomolecules
The structure of the biomolecules for our study has been 
used from pubchem. Pubchem is a composite database 
(http://pubchem.ncbi.nlm.nih.gov/) that is backed up 
by three primary databases, i.e. Pcsubstance, Pccom-
pund, PCBioAssay. Pubchem provides biological activity, 
chemical information of small molecules. Pcsubstance 
contains information about the substances; Pccompound 
contains information about chemical compounds, and 
PcBioAssay provides information about Bioassays.
CAM assay
The study have been approved from the ethical commit-
tee of Vellore Institute of Technology University(VITU), 
Vellore, India. Fertilized white leghorn chicken eggs were 
obtained from poultry farm. Eggs were incubated in an 
Incubator at 37  °C with 60 % humidity as mentioned in 
earlier [20]. A small window was made in the shell on day 
3 of chick embryo development under aseptic conditions. 
The window was resealed with adhesive tape after drug 
application, and eggs were returned to the incubator until 
day 11 of chick embryo development. Photography was 
performed on the following day, and eggs were discarded 
after photography.
HT‑29 cell culture
HT-29 cell culture was performed using DMEM, FBS, 
antibiotic and these cells were subcultured for biomol-
ecule administration using standard protocol.
Cell migration assay
Cell migration assay was studied using cell scratch assay 
at 70 % confluency and measuring the distance of scratch 
after 24, 48 h of scratch in HT-29 cell.
Pharm Mapper
Chemical compounds have been downloaded from 
the Pubchem database (http://pubchem.ncbi.nlm.nih.
gov/) in MDL SDF file format and have been loaded in 
PharmMapper server (http://59.78.96.61/pharmmap-
per/submit_file.php) with the options for searching of 
all potential candidates available in the PharmTargetDB. 
Furthermore, all the targets important for the process of 
angiogenesis have been identified, and their scores have 
been summarized in Fig. 1.
PharmMapper [19] is a web server for identifying the 
potential target candidates for a given probe (drugs, 
natural products). It adopts an alternative approach of 
pharmacophore mapping for potential drug targets. It 
possesses highly efficient and robust high-throughput 
mapping technique to identify target candidates from the 
databases within the short period of time. PharmMapper 
has been backed up by various databases that involve 
TargetBank, DrugBank, BindingDB and PDTD. Pharm-
Mapper accepts files in different formats in Tripos Mol2 
or MDL SDF (http://59.78.96.61/pharmmapper/sub-
mit_file.php) that identifies best mapping poses and out-
putted top N potential drug targets against all targets in 
PharmTargetDB. With the submission of new molecules, 
fit scores have been calculated first, which is used to fur-
ther calculate the normalized fit score. Moreover, every 
fit score of a specific pharmacophore has been compared 
to the fit score matrix to measure its score level among 
all the scores of the pharmacophore to find the Z′-score 
that adds more statistical meaning and confidence of 
comparison.
Colon cancer genome sequence analysis
Colon cancer genome sequence analysis information was 
taken from ICGC pooled data.
Molegro virtual docker (Version‑6.0)
In this study protein–ligand, docking was performed 
with the help of Molegro Virtual Docker [21] for predict-
ing the possible protein–ligand interactions (MVD).
Statistics
The statistics has been done using the excel software. Sta-
tistical significance was accepted at p < 0.05.
Result
Comparative chemical/structural/physical analysis 
and source of origin study of luteolin, lectin and lupeol
Retinoic acid can be naturally derived from carrot, 
pumpkin, squash, and sweet potatoes. Its IUPAC name 
is nona 2,4,6,8 tetraenoic acid with molecular mass 
is 300  g/mol, melting point is 180  °C, boiling point is 
175 °C, pH = 4.9 and it is soluble in water. Another com-
pound, luteolin can be naturally derived from olive oil, 
pepper, parsley. The molecular mass is 286 g/mol, melt-
ing point is 330 °C and boiling point is 660 °C, pH = 7.8 
and it is soluble in alkaline solvent while lupeol can be 
naturally isolated from mango, aloe leaves, ginseng oil. 
The molecular mass of lupeol is 426 g/mol, melting point 
is 210  °C and boiling point is 488  °C, pH  =  4.9 and it 
is soluble in water. Lectin is a glycoprotein with sugar 
chains, and its isoelectric point is 4.5; molecular mass is 
104–112 kDa and it can be naturally isolated from peas, 
cherries and sweet pepper as mentioned in Table  1 in 
Fig. 2A.
The structure of luteolin has a hydroxyl group while 
lupeol has a methyl group like the positive control reti-
noic acid and lectin has multiple sugar chains. Therefore, 
we can summarize that based on structural analysis lute-
olin is the best in targeting angiogenesis.
Page 4 of 10Ambasta et al. J Transl Med  (2015) 13:307 
Comparative anti‑angiogenic analysis of biomolecules, 
luteolin, lectin and lupeol on CAM Assay
Chick chorio-allantoic membrane (CAM) assay is one of 
the most reliable angiogenesis assays. The biomolecules 
have been administered on CAM and visualized for its 
effect after 24, 48 h in a concentration and dose depend-
ent manner as shown in Fig. 2B. The quantitation of angi-
ogenesis was calculated based on thickness of the vessel, 
branching, sprouting of new vessels and the diameter 
using software and manual counting. We examined the 
effect of luteolin, lupeol, lectin and retinoic acid on CAM 
assay. It was observed that luteolin inhibited angiogen-
esis better compared to lectin and lupeol. Further, these 
biomolecules were administered on HT-29 cell culture to 
check its anti-cancerous property.
Comparative anti‑cancerous analysis of biomolecules, 
luteolin, lectin and lupeol on HT‑29 cell culture
The biomolecules luteolin, lectin and lupeol were admin-
istered on HT-29 cell culture and its effect was observed 
after 24 and 48  h as shown in Fig.  3a, b. Under these 
experimental conditions, the cells were photographed 
using a microscope and cell viability was performed using 
trypan blue analysis. The statistical analysis of cell viabil-
ity demonstrates that luteolin is better in inhibiting cell 
growth at the lower dose compared to lectin and lupeol. 
In pilot study, we observed luteolin was the best amongst 
the compared drugs therefore; cell migration effect of 
luteolin was performed via scratch assay as shown in 
Fig. 3c, d and we observed that luteolin had the best effi-
cacy to inhibit the cell migration at 80  μM in 48  h.  In 
VEGF Mutaon Type of mutaon Chromosome Cancer
VEGF A C/T, A/T Single base substuon Chr 6 Colorectal
VEGF B A/A, C/T
Single base substuon and 
deleon Chr 11 Colorectal
VEGF C C/T, G/A. G/T Single base substuon Chr 4 Colorectal
a
b
Fig. 1 a It demonstrates fit score for target molecule of biomolecules and b shows the pooled data for VEGF A, B, C from ICGC pooled data demon-
strating identified point mutation in VEGF in colorectal cancer
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summary, we can say that luteolin is better in inhibiting 
angiogenesis, cell proliferation and cell migration.
Comparative analysis of potential target signaling 
mechanism of biomolecules, luteolin, lectin and lupeol
We next investigated the target signaling molecule of 
these biomolecule using software analysis. Studies have 
demonstrated certain target sites for these biomolecules 
but in order to get a broader view about the target sites 
and decide future target sites; software analysis was per-
formed using PharmMapper. PharmMapper is a web 
server for identifying the potential target candidates for a 
given probe (drugs, natural products). It adopts an alter-
native approach of pharmacophore mapping for poten-
tial drug targets. It possesses highly efficient and robust 
high-throughput mapping technique to identify target 
candidates from the databases within a short period of 
time. PharmMapper has been backed up by various data-
bases that involve TargetBank, DrugBank, BindingDB 
and PDTD. PharmMapper accepts files in different for-
mats in Tripos Mol2 or MDL SDF (http://59.78.96.61/
pharmmapper/submit_file.php) that identifies best map-
ping poses and outputted top N potential drug targets 
against all targets in PharmTargetDB. With the submis-
sion of new molecules, fit scores have been calculated 
first, which is used to further calculate for normalized 
fit score. Moreover, every fit score of a specific pharma-
cophore has been compared to the fit score matrix to 
measure its score level among all the scores of the phar-
macophore to find the Z′-score that adds more statistical 
meaning and confidence of comparison.
Table 2 of Fig. 1a enlists different potential downstream 
targets for the biomolecules of our interest. Luteolin tar-
get is bFGFR, VEGF, HGFR, Caspase 3, MAPK14, hya-
luronatelyase and CDK6. The positive control retinoic 
acid has MAPK1, Caspase 3, bFGFR1, VEGF, hyaluronate 
lyase and CDK2 downstream target. The biomolecule 
lupeol also has the target candidate listed as MAPK10, 
HGFR, VEGF, hyaluronate lyase etc. The common tar-
get sites are VEGF, bFGFR1, HGFR, caspase3 and CDK2. 
Upon comparing the literature research output with the 
predicted targets, we find intriguing correlation between 
prediction and actual interest. Therefore, the best tar-
get site for future comparison can be VEGFR1, bFGFR1, 
HGFR, caspase3 and CDK2.
ICGC pooled data demonstrate that VEGF ligand is 
mutated in colon cancer tissues as shown in Table  3 
of Fig.  1b. Hence the receptor of VEGF have been 
screened for conserved sequence domain in VEGFR-
biomolecule(s) docking site.
These result suggests that one of the important target 
molecule of these biomolecule is VEGF and its receptor. 
Interestingly, VEGF ligand has been found to be mutated 
in colon cancer, indicating that VEGF is not only impor-
tant for tumour development and progression but it can 
also act as a therapeutic target molecule for colon cancer.
Comparative analysis of protein–ligand docking affinity 
of biomolecules, luteolin, lectin and lupeol with VEGF
Numerous studies have shown that VEGFR1 is a marker 
for angiogenesis, therefore, the docking affinity of our 
biomolecules of interest has been checked against the 
VEGF receptors in Fig. 4a. In this study protein–ligand, 
docking was performed with the help of Molegro Virtual 
Docker for predicting the possible protein–ligand inter-
actions (MVD).
To determine protein(VEGFR1)-ligand(Biomolecules) 
docking, VEGFR1 protein (PDB id: 1VPF) was used as a 
target molecule/macromolecule. Docking of target pro-
tein was performed with the four ligands namely; lupeol, 
lectin, retinoic acid and luteolin. The docked poses were 
analyzed individually, and the best pose was reported. 
The interactions between the ligands and target protein 
were represented pictorially. The final results of docking 
were predicted after evaluating all the possible conforma-
tions/orientations of the given ligands within the binding 
pocket of target protein in terms of the hydrogen bond 
energy, steric interactions. Further, comparative analyses 
of all the four ligands were carried out for the prediction 
of ligand with the highest potency towards target protein. 
Retinoic acid formed two hydrogen bonds with Cysteine 
1018 residue of Target protein whereas; lupeol formed 
two hydrogen bonds with Cysteine 912 and Glycine 915 
residues. The overall interaction energy, including hydro-
gen bond energy was also low for these two ligands. 
Though, lectin formed maximum number of hydrogen 
bonds with the target protein, it also depicted highest 
steric interactions but the overall interaction energy was 
low. It was observed that luteolin formed seven hydrogen 
bonds with the target protein at Ile1038, Val892, Glu878, 
Cys1018, Arg102 and two bonds with Ile1019, the steric 
interactions were less but the overall interaction energy 
was highest for luteolin. Therefore, this study proposes 
that luteolin has the highest inhibitory activity against 
target protein in terms of binding efficiency as compared 
to other three ligands that were used in this study.
As there are different types of VEGF receptors found on 
tissues, hence multiple alignments have been performed 
for the three VEGF receptors to check for the conserved 
sequence at docking sites of the biomolecules. There-
fore, Sequence alignment has been done for VEGFR. 
The alignment shows conserved sequence at the dock-
ing sites as shown in Fig. 4b. As the docking sequence is 
conserved between the receptors, hence luteolin can be a 
good target for colon cancer therapy overcoming the has-
sles of non specific targeting.
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Fig. 2 A Structure, IUPAC name, physical properties and origin of Biomolecules in Table 1. B On the left-hand side, demonstrates CAM assay with 
biomolecules like luteolin, lupeol and lectin. Table 1B on the right-hand side shows time dependent and concentration dependent CAM assay with 
biomolecules
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Discussion
In recent studies, several reports have been focused on 
individual role of luteolin, lupeol and lectin in tumour 
therapy but till date no study has compared these bio-
molecules. In this study, luteolin was found to be one of 
the best inhibitors of angiogenesis as compared with lec-
tin and lupeol via CAM assay. In addition, Luteolin has 
been found to be comparatively better in its anti-cancer-
ous effect as compared with lupeol and lectin as observed 
from HT-29 cell culture, cell migration assay and docking 
with VEGFR1. The purpose of this study was to compare 
the anti cancerous and anti-angiogenic role of biomol-
ecules and analyze the docking domain of these biomol-
ecules on the target site. Therefore, comparison analysis 
of the biomolecules have illuminated new facts that may 
contribute for future analysis.
To ensure the accuracy of comparison, quantitative 
analysis of CAM assay, HT-29 cell culture assay and cell 
migration assay has been done. Moreover another impor-
tant question about the size, origin and chemical struc-
ture of the biomolecules have been addressed in Fig.  2. 
Due to the difference in the size of the biomolecules, it 
is expected that the steric hindrance will be different. 
Therefore, we compare a large protein versus small bio-
molecules for cancer therapy like luteolin, lupeol and 
positive control retinoic acid. We find that in our study, 
the large protein due to its size and steric hindrance 
poses several problems in its anti-angiogenic effect 
on CAM assay and docking with VEGF. Studies have 
reported that small molecule due to its size is better in 
permeabilization of the cell. Moreover in this study, the 
smaller biomolecules like luteolin and lupeol are better in 
inhibiting angiogenesis on CAM assay and docking with 
VEGF. Amongst the two small biomolecule lupeol and 
luteolin, luteolin has been found to be better in inhibit-
ing angiogenesis and VEGF docking. Irrespective of the 
size of biomolecules, an obvious question arises about 
the target of these biomolecules in signaling for cancer 
progression.
Many reports demonstrates several target of these bio-
molecules but there is no platform where we can com-
pare the target of the biomolecule using a score. Hence a 
software analysis has been used to predict the target site 
of these biomolecules. Importantly, the predicted result 
as shown in Fig. 1 demonstrates that the higher fit scores 
for retinoic acid are for bFGF, VEGFR2, hyaluronatelyase, 
MAPK and caspase 3. The higher fit scores for luteolin 
are bFGFR, VEGFR2, CDK2/6, hyaluronatelyase and 
MAPK14. The higher fit scores for lupeol are MAPK10, 
CDK2, HGFR, VEGFR2, hyaluoronate lyase. Several 
reports have confirmed the target site of lectin as VEGF, 
HGF, MAPK, hyaluronic acid. Hence it can be deduced 
that VEGF, HGF, MAPK and hyaluronate lyase can be a 
common target molecule for these biomolecules.
The new identified targets for cancer therapy in future 
using luteolin can be CDK2, CDK6, HGFR, MAPK14, 
FGF. Earlier reports demonstrated direct involvement 
of luteolin with VEGF [22, 23]. It has been confirmed 
both by prediction and actual reports that VEGFR have 
role in tumour development and progression. This study 
also confirms the mutated VEGF ligand in colorectal 
cancer. We have chosen VEGFR1 for docking analysis 

















Luteolin Lupeol Lecn Renoic
acid
60μM
10 μM 20 μM 40 μM 80 μM 
Luteolin 3 cm 4 cm 4.5 cm 5 cm
Lecn 3 cm 3.2 cm 3.5 cm 4 cm
Lupeol 3 cm  3.1 cm 3.3 cm 3.5 cm
Renoic Acid 3 cm 4.1 cm 4.6 cm 5.2 cm
Luteolin 24 hr 48 hr 72 hr
10 μM 3 cm 3 cm 3 cm
20 μM 3 cm 3.2 cm 4 cm
40 μM 3.1 cm 3.5 cm 4.5 cm




Fig. 3 a Demonstrates concenteration dependent administration 
of biomolecules on HT-29 cell while b shows the live cell at 60 μM. c 
shows the cell migration assay via scratch assay
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to be a positive regulator of angiogenesis. The fit score 
for VEGFR is highest for retinoic acid, known to inhibit 
angiogenesis, which is followed by luteolin and lupeol for 
its fit score. Therefore, this study demonstrates for the 
first time that amongst the biomolecules comprising of 
a large protein lectin and two small molecules, luteolin 
and lupeol along with the positive control retinoic acid, 
luteolin is better in inhibiting angiogenesis and docking 
with VEGF. Therefore, future cancer therapy can target 
signaling pathway with luteolin as compared with lupeol 
and lectin.
The anti-cancerous property of luteolin is good in 
HT-29 cells, but it is compromised in colon tumour cells. 
It may be due to presence of multi drug resistant (MDR) 
gene in colon cancer cells [24, 25].
Although, lectin has been reported to be anti-cancer-
ous [26–29], but it is a large molecule compared with 
luteolin and lupeol. Luteolin and lupeol are small in size 
and have demonstrated to be better in inhibiting angio-
genesis compared with lectin. Moreover, it has been 
shown by others that luteolin alone, and in combination 
with gefitinib or epigallocatechin-3-gallate [30, 31] can 
inhibit another cancer but till date, nobody has shown 
the comparative effects of luteolin, with lupeol or lectin 
in colon cancer. Hence this manuscript is showing for the 
first-time comparative anti-angiogenic effect of luteolin 
with lupeol and lectin.
Conclusion
Therefore, we can conclude that our study addressed 
a potentially important comparison criteria amongst 
the biomolecules lectin, luteolin and lupeol, luteolin 
has been found to be better in inhibiting angiogenesis 
and docking with VEGF receptors. The receptors are 
conserved at the docking sites, indicating that VEGF 
receptors can be safely targeted for cancer therapy via 
luteolin. Hence, it can be concluded that in future, 
luteolin can be preferred over lectin and lupeol for 
its anti-cancerous and anti-angiogenic property and 
docking site of these biomolecules are conserved at 
VEGFR domain.
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Fig. 4 a Demonstrates the structure of the biomolecule and structure of VEGFR1 along with the docking site of the biomolecule on VEGFR1 
sequence. b Shows multiple alignment of VEGFR1, 2, 3 along with marked amino acid sequence for the biomolecules luteolin, lupeol and lectin. 
Multiple sequence alignments of vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3): amino acid residues with similar nature 
are highlighted with same colour. Further, active site residues of VEGFR1 identified upon docking with retinoic acid (V841, V892, C1018, C1039), 
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are marked with pink, dark blue, dark green and purple colour arrows respectively
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